This week, my youngest son, Caeleb, visited the pediatric clinic for his last comprehensive exam there. My mind went in a million directions as I recalled meeting his hematologist, Shirley Abraham, MD. She witnessed the tough times when my son struggled through many painful spontaneous bleeding episodes because…

The new year isn’t exactly kicking off on a high note for me. At the end of last year, I headed to Schaumburg, Illinois, to spend Christmas with my family only for my dental crown to crack in half during the trip and decide to make…

In the final days of 2023, an adult with hemophilia A named Maxwell became the first person in the U.S. to receive treatment with the one-time gene therapy Roctavian (valoctocogene roxaparvovec-rvox) — approved in June of last year — outside of clinical trials. “Receiving this treatment is liberating…

My oldest son, Julian, possesses many talents. Last August, he moved back home to save some money. He continues auditioning for theaters, hoping to make a living as a professional entertainer. I’m a little biased (OK, a lot), but his voice is in tip-top condition, and he can adequately compete…

In the middle of a work meeting, I stumbled upon an intriguing concept that resonated with me on a personal level: the good-better-best goal system. This is a goal-setting approach that allows you to set goals in three tiers that align with your individual capabilities. As I delved…

As we begin a new year, I can’t help but feel the power of hope permeate the air as conversations turn to new opportunities. Those of us in the bleeding disorders community long for new treatments that offer possibilities for a better quality of life. We pray that the…

The adventure of life is filled with ups and downs. Focusing on a word instead of on New Year’s resolutions can be a powerful practice when navigating a bleeding disorder. A focus word serves as a daily reminder and source of motivation, providing a lens through which to…

Healthcare costs are comparable for male patients with hemophilia A who are treated with either Adynovate (rurioctocog alfa pegol) or Eloctate (efmoroctocog alfa), according to a real-world study in the U.S. “Results from this analysis may be used to inform product coverage and treatment decisions valuable for both…

Soon, I’ll leave sunny Florida for the northern tundra of Madison, Wisconsin, and Schaumburg, Illinois, to be with my family for Christmas. As I prepare to spend time with my loved ones, I can’t help but appreciate the significance of this trip: It marks my first Christmas journey without…

SerpinPC, an experimental treatment being developed by Centessa Therapeutics, continues to be safe when used for up to nearly three years and to almost zero out the number of bleeds in adults with severe hemophilia A or B. Those findings come from a one-year extension of the…